Tandem Diabetes (TNDM) Misses Q2 EPS by 38c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Tandem Diabetes Care (TNDM) PT Lowered to $51 at Barclays
August 7, 2025 8:27 AM EDTBarclays analyst Matt Miksic lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $51.00 (from $53.00) while maintaining a Overweight rating.
The analyst comments "Q2 sales were a touch above consensus, with upside OUS offset by a shortfall in the U.S. Mgmt... More
